Insider · CIK 0001261506
Karen A Dawes
Files at RGEN (REPLIGEN CORP), BRNS (Barinthus Biotherapeutics plc.). First filing Feb 28, 2024, latest Dec 18, 2025.
In brief
Karen A Dawes files SEC Form 4 as director at RGEN (REPLIGEN CORP), and also at BRNS (Barinthus Biotherapeutics plc.). Since Feb 28, 2024, Karen A Dawes has reported 0 open-market buys worth $0 and 2 open-market sells worth $238k, the latest filed on Dec 18, 2025.
A track record needs three past buys with six months of prices behind them; Karen A Dawes has 0, so none is measured yet.
The newest scored trade: sold $44k of RGEN on Dec 17, 2025, filed Dec 18, 2025, scored 21 (weak). In the last 12 months: 0 buys worth $0 and 1 sell worth $44k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
RGEN: REPLIGEN CORP
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 21Weak | RGENsell REPLIGEN CORP | $44k 275 shares | -0% | +44% from low-10% from high | |
| 27Weak | REPLIGEN CORP | $193k 1,000 shares | -1% | +69% from low-8% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Dec 17, 2025 | RGEN REPLIGEN CORP | 275 0.00% of outstanding | $44k | Dec 17, 2025 | none |
| Feb 27, 2024 | RGEN Repligen Corporation | 1,000 0.00% of outstanding | $193k | Feb 27, 2024 | none |
Transactions
Every row this insider has filed, 20 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 9, 2026 | BRNS Barinthus Biotherapeutics plc. | DDisposition to issuer Ordinary Shares | -1,700 | - | - | 0 | 35 d ago |
| Sep 9, 2026 | BRNS Barinthus Biotherapeutics plc. | DDisposition to issuer Share Option (Right to Buy)derivative | -34,328 | $0.00 | $0 | 0 | 35 d ago |
| Sep 9, 2026 | BRNS Barinthus Biotherapeutics plc. | DDisposition to issuer Share Option (Right to Buy)derivative | -18,604 | $0.00 | $0 | 0 | 35 d ago |
| Sep 9, 2026 | BRNS Barinthus Biotherapeutics plc. | DDisposition to issuer Share Option (Right to Buy)derivative | -19,197 | $0.00 | $0 | 0 | 35 d ago |
| Sep 9, 2026 | BRNS Barinthus Biotherapeutics plc. | DDisposition to issuer Share Option (Right to Buy)derivative | -19,516 | $0.00 | $0 | 0 | 35 d ago |
| Sep 9, 2026 | BRNS Barinthus Biotherapeutics plc. | DDisposition to issuer Share Option (Right to Buy)derivative | -20,174 | $0.00 | $0 | 0 | 35 d ago |
| May 14, 2026 | RGEN REPLIGEN CORP | AGrant or award Common Stock | +995 | $0.00 | $0 | 92,816 | May 18, 2026 |
| May 14, 2026 | RGEN REPLIGEN CORP | AGrant or award Stock Option (Right to Buy)derivative | +2,239 | $0.00 | $0 | 2,239 | May 18, 2026 |
| Dec 17, 2025 | RGEN REPLIGEN CORP | SOpen-market sale Common Stock | -275 | $161.00 | $44k | 91,821 | Dec 18, 2025 |
| Jun 10, 2025 | BRNS Barinthus Biotherapeutics plc. | AGrant or award Share Option (Right to Buy)derivative | +20,174 | $0.00 | $0 | 20,174 | Jun 11, 2025 |
| May 15, 2025 | RGEN REPLIGEN CORP | AGrant or award Common Stock | +973 | $0.00 | $0 | 92,096 | May 19, 2025 |
| May 15, 2025 | RGEN REPLIGEN CORP | AGrant or award Stock Option (Right to Buy)derivative | +1,800 | $0.00 | $0 | 1,800 | May 19, 2025 |
| Jun 14, 2024 | RGEN REPLIGEN CORP | MOption exercise Common Stock | +2,953 | $67.71 | $200k | 88,170 | Jun 14, 2024 |
| Jun 14, 2024 | RGEN REPLIGEN CORP | MOption exercise Stock Option (Right to Buy)derivative | +2,953 | $0.00 | $0 | 0 | Jun 14, 2024 |
| May 16, 2024 | RGEN REPLIGEN CORP | AGrant or award Common Stock | +803 | $0.00 | $0 | 88,170 | May 20, 2024 |
| May 16, 2024 | RGEN REPLIGEN CORP | AGrant or award Stock Option (Right to Buy)derivative | +1,576 | $0.00 | $0 | 1,576 | May 20, 2024 |
| May 10, 2024 | BRNS Barinthus Biotherapeutics plc. | AGrant or award Share Option (Right to Buy)derivative | +19,516 | $0.00 | $0 | 19,516 | May 14, 2024 |
| Feb 27, 2024 | RGEN REPLIGEN CORP | MOption exercise Common Stock | +4,626 | $42.07 | $195k | 88,367 | Feb 28, 2024 |
| Feb 27, 2024 | RGEN REPLIGEN CORP | SOpen-market sale Common Stock | -1,000 | $193.35 | $193k | 87,367 | Feb 28, 2024 |
| Feb 27, 2024 | RGEN REPLIGEN CORP | MOption exercise Stock Option (Right to Buy)derivative | +4,626 | $0.00 | $0 | 0 | Feb 28, 2024 |
Questions about Karen A Dawes
Answered from the filings on this page, as of the latest one.
Is Karen A Dawes buying or selling?
In the last 12 months Karen A Dawes reported 0 open-market buys worth $0 and 1 open-market sell worth $44k on SEC Form 4; the latest was sold $44k of RGEN on Dec 17, 2025. Grants, option exercises and tax withholding are not counted.
How did Karen A Dawes's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Karen A Dawes has 0.
Where does Karen A Dawes file Form 4?
Karen A Dawes has filed Form 4 at RGEN (REPLIGEN CORP); BRNS (Barinthus Biotherapeutics plc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.